Trials / Withdrawn
WithdrawnNCT01344109
A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Leo W. Jenkins Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a pilot study evaluating the use of tumor derived exosomes as a marker for response to therapy in women receiving neoadjuvant chemotherapy for newly diagnosed breast cancer. Tumor derived exosome analysis may be a novel diagnostic and prognostic biosignature in breast cancer, which could prove to be a tool for earlier diagnosis, more effective treatments, and improved markers of response in order to increase survival rates.
Conditions
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2011-04-28
- Last updated
- 2017-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01344109. Inclusion in this directory is not an endorsement.